JPS6245846B2 - - Google Patents
Info
- Publication number
- JPS6245846B2 JPS6245846B2 JP49072169A JP7216974A JPS6245846B2 JP S6245846 B2 JPS6245846 B2 JP S6245846B2 JP 49072169 A JP49072169 A JP 49072169A JP 7216974 A JP7216974 A JP 7216974A JP S6245846 B2 JPS6245846 B2 JP S6245846B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- corticoid
- pregnadiene
- acid
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003470 adrenal cortex hormone Substances 0.000 claims description 10
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 6
- -1 hydroxymethylene group Chemical group 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 208000026935 allergic disease Diseases 0.000 description 5
- 210000002345 respiratory system Anatomy 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010039083 rhinitis Diseases 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 229930189077 Rifamycin Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229960003292 rifamycin Drugs 0.000 description 1
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2332663A DE2332663C2 (de) | 1973-06-23 | 1973-06-23 | Verwendung von Kortikoid-Wirkstoffen zur Inhalationstherapie |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5047967A JPS5047967A (es) | 1975-04-28 |
| JPS6245846B2 true JPS6245846B2 (es) | 1987-09-29 |
Family
ID=5885228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP49072169A Expired JPS6245846B2 (es) | 1973-06-23 | 1974-06-24 |
Country Status (13)
| Country | Link |
|---|---|
| JP (1) | JPS6245846B2 (es) |
| BE (1) | BE816709A (es) |
| DD (1) | DD112437A5 (es) |
| DE (1) | DE2332663C2 (es) |
| DK (1) | DK337574A (es) |
| ES (1) | ES427480A1 (es) |
| FR (1) | FR2233987B1 (es) |
| GB (1) | GB1479488A (es) |
| IE (1) | IE39516B1 (es) |
| IL (1) | IL45087A (es) |
| NL (1) | NL184724C (es) |
| SE (1) | SE7408091L (es) |
| ZA (1) | ZA744022B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX3864E (es) | 1975-05-27 | 1981-08-26 | Syntex Corp | Un proceso para prepara el compuesto cristalino 6-fluiro-11b 21-dihiroxi-16 17-isopropilidendioxipregna-1 4-dien-3 20-diona |
| DE2829953A1 (de) * | 1978-07-03 | 1980-01-24 | Schering Ag | Pharmazeutische zubereitung zur behandlung der kolitis ulcerosa und kolitis granulomatosa |
| US5215979A (en) * | 1985-12-19 | 1993-06-01 | Aktiebolaget Draco | 16,17-acetalsubstituted pregnane 21-oic acid derivatives |
| JP4893999B2 (ja) | 2004-10-22 | 2012-03-07 | 小野薬品工業株式会社 | 吸入用医薬組成物 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1792207A1 (de) * | 1967-08-08 | 1971-11-04 | Fisons Pharmaceuticals Ltd | Pharmazeutische Praeparate |
| DE2150268A1 (de) * | 1971-10-04 | 1973-04-12 | Schering Ag | Neue pregnansaeure-derivate |
| JPS4828620A (es) * | 1971-08-06 | 1973-04-16 | ||
| JPS5046820A (es) * | 1971-06-22 | 1975-04-25 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB799902A (en) * | 1954-08-11 | 1958-08-13 | Merck & Co Inc | Therapeutic preparations |
| US3320125A (en) * | 1964-04-28 | 1967-05-16 | Merck & Co Inc | Inhalation aerosol composition |
| DD95565B1 (de) * | 1971-10-04 | 1986-10-29 | Schering Ag | Verfahren zur herstellung neuer pregnansaeurederivate |
| DE2264003C2 (de) * | 1972-12-22 | 1982-11-04 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Neue Pregnansäure-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate |
| DE2319479C2 (de) * | 1973-04-14 | 1982-10-28 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Pregnansäure-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate |
-
1973
- 1973-06-23 DE DE2332663A patent/DE2332663C2/de not_active Expired
-
1974
- 1974-06-19 SE SE7408091A patent/SE7408091L/ not_active Application Discontinuation
- 1974-06-20 ES ES427480A patent/ES427480A1/es not_active Expired
- 1974-06-20 IE IE1292/74A patent/IE39516B1/xx unknown
- 1974-06-21 BE BE145751A patent/BE816709A/xx not_active IP Right Cessation
- 1974-06-21 IL IL45087A patent/IL45087A/xx unknown
- 1974-06-21 NL NLAANVRAGE7408421,A patent/NL184724C/xx not_active IP Right Cessation
- 1974-06-21 ZA ZA00744022A patent/ZA744022B/xx unknown
- 1974-06-24 GB GB27902/74A patent/GB1479488A/en not_active Expired
- 1974-06-24 DK DK337574A patent/DK337574A/da unknown
- 1974-06-24 JP JP49072169A patent/JPS6245846B2/ja not_active Expired
- 1974-06-24 FR FR7421859A patent/FR2233987B1/fr not_active Expired
- 1974-06-24 DD DD179417A patent/DD112437A5/xx unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1792207A1 (de) * | 1967-08-08 | 1971-11-04 | Fisons Pharmaceuticals Ltd | Pharmazeutische Praeparate |
| JPS5046820A (es) * | 1971-06-22 | 1975-04-25 | ||
| JPS4828620A (es) * | 1971-08-06 | 1973-04-16 | ||
| DE2150268A1 (de) * | 1971-10-04 | 1973-04-12 | Schering Ag | Neue pregnansaeure-derivate |
Also Published As
| Publication number | Publication date |
|---|---|
| SE7408091L (es) | 1974-12-23 |
| IE39516B1 (en) | 1978-10-25 |
| IL45087A (en) | 1978-04-30 |
| IE39516L (en) | 1974-12-23 |
| NL184724B (nl) | 1989-05-16 |
| DK337574A (es) | 1975-03-17 |
| NL7408421A (es) | 1974-12-30 |
| FR2233987A1 (es) | 1975-01-17 |
| BE816709A (fr) | 1974-12-23 |
| GB1479488A (en) | 1977-07-13 |
| DE2332663A1 (de) | 1975-01-16 |
| AU7042174A (en) | 1976-01-08 |
| DD112437A5 (es) | 1975-04-12 |
| DE2332663C2 (de) | 1986-07-31 |
| ZA744022B (en) | 1975-06-25 |
| ES427480A1 (es) | 1976-07-16 |
| FR2233987B1 (es) | 1977-07-08 |
| IL45087A0 (en) | 1974-09-10 |
| NL184724C (nl) | 1989-10-16 |
| JPS5047967A (es) | 1975-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5719123A (en) | Ciclosporin form for pulmonary administration | |
| JP6219016B2 (ja) | トレプロスチニル一水和物 | |
| JP3042867B2 (ja) | 呼吸疾患治療薬 | |
| AU2006259604A1 (en) | Substituted phenylphosphates as mutual prodrugs of steroids and beta -agonists for the treatment of pulmonary inflammation and bronchoconstriction | |
| JP2000502365A (ja) | 新規な組み合わせ | |
| JP2006502172A (ja) | 抗炎症性または抗アレルギー性アンドロスタン複合体 | |
| JP2000501732A (ja) | 抗炎症薬として有用な新規ステロイドナイトライト／ナイトレートエステル誘導体 | |
| HU214028B (en) | Process for producing cyclosporin derivatives and pharmaceutical compositions containing them | |
| SI9210065A (en) | Novel antiinflamatory and antialergic active compounds, glucocorticosteroids and processes for their preparation | |
| WO2010150014A1 (en) | 5r- 5 -deuterated glitazones for respiratory disease treatment | |
| Boobis | Comparative physicochemical and pharmacokinetic profiles of inhaled beclomethasone dipropionate and budesonide | |
| US20110086827A1 (en) | Combination medicament | |
| KR0124817B1 (ko) | 4-퀴놀린 카복실산 유도체를 포함하는 피부 및 점막-상피성 질환 치료용 약제학적 조성물 | |
| CA2538419A1 (en) | Use of ciclesonide for the treatment of respiratory diseases | |
| JPS6245846B2 (es) | ||
| JP6366696B2 (ja) | Ｓ−［４−（３−フルオロ−３−メチルブチリルオキシ）ブタ−２−イニル］６α，９α−ジフルオロ−１７α−（フラン−２−イル）カルボニルオキシ−１１β−ヒドロキシ−１６α−メチル−３−オキソアンドロスタ−１，４−ジエン−１７β−カルボチオアートを使用する炎症性病態の治療の方法 | |
| JPH11106339A (ja) | Ｃｒ２０３９を含有する吸入用医薬組成物 | |
| JP2002510310A (ja) | 抗喘息薬の新規配合 | |
| JP7254130B2 (ja) | 結晶多形および医薬組成物 | |
| CN116887840A (zh) | 甾体季铵化合物及其制备方法、制剂和用途 | |
| US4039668A (en) | Corticoid-containing inhalants | |
| TWI309164B (en) | Novel crystal form b of a known thiophenecarboxylic acid dodecahydrocyclopenta[a]phenanthrenyl ester,pharmaceutical composition comprising the same,use thereof, and method of preparing it | |
| WO1994013690A1 (en) | New steroids | |
| CZ20004774A3 (en) | Substituted beta-diketones and their use | |
| PT883628E (pt) | Derivados 17beta-(2-oxo-tetra-hidrofurano-4-il)-tio-androstano (derivados de grupo 17beta-(lactona do acido gama-butirico)-tio) para o tratamento de inflamacoes composicoes farmaceuticas e processo para a sua preparacao |